Gabriela Gruia

Learn More
PURPOSE This phase III, randomized, open-label, multicenter study compared the overall survival associated with irinotecan plus gemcitabine (IRINOGEM) versus gemcitabine monotherapy (GEM) in patients(More)
CONTEXT Long-term survival of patients with metastatic colorectal cancer has been achieved only in patients who underwent complete resection of metastases. Such surgery could be performed in a(More)
BACKGROUND Irinotecan is an active drug in colorectal cancer. In patients with liver metastases, hepatic arterial infusion of irinotecan could theoretically result in higher exposure to the drug. In(More)
PURPOSE To evaluate the feasibility of administering irinotecan as a continuous intravenous infusion for 14 to 21 days. PATIENTS AND METHODS Patients with solid tumors refractory to standard(More)
Although irinotecan 350 mg m−2 is a standard option for relapsed/refractory advanced colorectal cancer, there is some evidence that suggests that a higher dose may be more effective, with acceptable(More)
3503 Background: OS has been the 1o endpoint for phase III MCRC registration trials. However, increasing numbers of efficacious agents have extended OS and added therapeutic complexity. Evaluation of(More)